GlaxoSmithKline PLC (GSK,GSK.L) on Wednesday announced the results of a U.S. Food and Drug Administration Oncologic Drugs Advisory Committee meeting to discuss the supplemental New Drug Application for Avodart for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen.
When asked if the dutasteride risk/benefit profile is favorable for reduction in the risk of prostate cancer in this target population, the committee voted 14 against, 2 in favor, and 2 abstentions, the company said.
The FDA is not required to follow the panel's advice, but often does.
"While we are disappointed by the Committee's conclusions on dutasteride as a prostate-cancer risk-reduction therapy, it is important to note that dutasteride has an established efficacy and safety profile in the treatment of BPH, including trials involving 10,000 men and the cumulative of 5.5 million years of patient exposure," said Anne Phillips, vice president, medicine development leader, Oncology Research and Development, GlaxoSmithKline. "We will continue to work with the FDA on the review of the sNDA."
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.